Business Wire

WESTLAKE-CORPORATION

11.7.2024 21:17:27 CEST | Business Wire | Press release

Share
Westlake Vinnolit Customers Appreciate Joint Efforts on Decarbonization

This year, a particularly large number of plastics converters took part in the annual polymer producers’ assessment sponsored by the Polymers for Europe Alliance. All polymers users in Europe had until mid-May to vote and rate their polymer suppliers' performance during the past 12 months. Following this year's key criteria delivery reliability, circularity, quality, communication, innovation and commitment to the European Market, Westlake Vinnolit won the PVC category with 92% of the vote. "We are delighted with this great success and would like to thank our customers for their continued trust and inspiration," said Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia, and Managing Director of Westlake Vinnolit. "At the same time, this is the greatest incentive for us to continue to improve."

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711680182/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

‘Supplier of the year for PVC’ and ‘Overall Award – Decarbonisation’ for Westlake Vinnolit: Ron Marsh, Chairman of the Polymers for Europe Alliance (left), congratulated Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia. (Photo: Polymers for Europe Alliance)

Furthermore, Westlake Vinnolit also won the ‘Overall Award – Decarbonization.’ “The PVC Award is a major accolade, surpassed only by being awarded the number one plastics supplier in terms of decarbonization,” said Schellerer, who received the awards and certificates from Ron Marsh, Chairman of the Alliance, and EuPC President Benoît Hennaut, at the ceremony that took place at the European Plastics Converters’ conference ‘A Circular Future with Plastics’ in Brussels. “The de-fossilization of plastics is an important building block in the effort to combat climate change and one of the biggest challenges for the industry. With our CO2-saving GreenVin® product line, we actively support our customers in helping them to reduce Scope 3.1 emissions and advance their sustainability goals.”

Vinnolit GreenVin® PVC is produced entirely with electricity from renewable energy sources, backed with European high-quality certificates for renewable energies (Guarantees of Origin / HKNs) and saves around 25% CO2 equivalents in comparison to conventionally produced ®Vinnolit PVC. The respective carbon footprint was calculated by Sustainable AG in accordance with the ISO 14067 standard and certified by TÜV Rheinland. GreenVin® bio-attributed PVC, in addition, uses renewable ethylene based on 2nd generation biomass, which increases the CO2 savings to around 90%, taking into account the biogenic CO2 fixation. Vinnolit GreenVin® bio-attributed PVC is mass-balanced and certified according to ISCC PLUS and REDcert2. The favorable product and processing properties desired by customers remain unchanged.

The Polymers for Europe Alliance was initiated by the European Plastics Converters association (EuPC) to provide factual public information on the status of the polymer supply situation in Europe and to engage in a constructive dialogue with the supply base. The initiatives of the Alliance also include the Polymer Producers Awards for Europe. In this Europe-wide customers’ satisfaction survey all users of polymers in Europe can rate their suppliers of the year.

ABOUT WESTLAKE VINNOLIT

As a leading manufacturer for PVC and an important partner for caustic soda, Westlake Vinnolit offers individual solutions for customers from a wide range of industries, such as the construction sector, the automotive industry, medical technology or pulp and paper production. As a manufacturer of high-quality PVC specialties, Westlake Vinnolit is a global market leader. At its headquarters in Ismaning near Munich and its four production sites in Burghausen, Gendorf, Knapsack and Cologne, 1,400 employees generate annual sales of more than €1 billion.

Westlake Vinnolit participates in the chemical industry's Responsible Care program for the continuous improvement of safety, health and environmental protection and supports VinylPlus®, the European PVC industry's voluntary commitment to sustainable development, as an "Official Partner" financially, ideally and through active participation. For more information visit www.westlakevinnolit.com

ABOUT WESTLAKE CORPORATION (WLK)

Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the Company's web site at www.westlake.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711680182/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye